We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Familial Myeloproliferative Disorders

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT00666289
First Posted: April 24, 2008
Last Update Posted: September 4, 2017
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Collaborators:
Myeloproliferative Disorders-Research Consortium
National Cancer Institute (NCI)
Information provided by (Responsible Party):
Icahn School of Medicine at Mount Sinai
  Purpose
Myeloproliferative disorders occur in families, thus giving rise to the theory that it is a genetic disease that may be caused by an abnormal gene in the DNA that can be passed from one generation of family members to another. DNA can be gathered from family members through blood samples and the investigators will investigate (through DNA testing) to see if there are abnormal genes that may be responsible for causing the MPDs. Understanding which genes are responsible for causing MPDs can help develop ways to identify people who may be at risk for developing an MPD, allow for the development of better treatments, possibly a cure, or even prevent the development of MPDs.

Condition
Polycythemia Vera Essential Thrombocythemia Idiopathic Myelofibrosis

Study Type: Observational
Study Design: Observational Model: Family-Based
Time Perspective: Other
Official Title: Molecular Biology of Familial Myeloproliferative Disorders

Resource links provided by NLM:


Further study details as provided by Icahn School of Medicine at Mount Sinai:

Primary Outcome Measures:
  • To determine a linkage from the DNA analyzed to find a gene that will allow for genetic evaluation of families with MPDs. [ Time Frame: 3 years ]

Biospecimen Retention:   Samples With DNA
Blood samples from subjects and family members with myeloproliferative disease.

Enrollment: 17
Study Start Date: March 2008
Study Completion Date: June 20, 2015
Primary Completion Date: January 20, 2015 (Final data collection date for primary outcome measure)
  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   7 Years and older   (Child, Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
families with multiple member diagnosed with myeloproliferative disease
Criteria

Inclusion Criteria:

  • Families with 2 or more members diagnosed with polycythemia vera (PV), essential thrombocythemia (ET), PV and ET related myelofibrosis (PV-MF and ET-MF), idiopathic myelofibrosis (IM) or chronic myelogenous leukemia (CML).
  • Healthy family members of subjects diagnosed with a myeloproliferative neoplasm (MPN).
  • Participating subjects must be 7 years of age or older
  • A written assent, parental permission or consent must be obtained prior to any study procedures being performed.

Exclusion Criteria:

  • Subjects who have a known acquired cause of polycythemia (increased hemoglobin/hematocrit), such as people living in high altitudes (in excess of 14,000 feet), subjects with heart disease, left to right heart shunt, severe hypoxia, cyanotic congenital heart disease, or severe pulmonary disease, will be excluded from this study, secondary forms of thrombocytosis and secondary forms of myelofibrosis.
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00666289


Locations
United States, District of Columbia
Georgetown University
Washington, D.C., District of Columbia, United States, 20057
United States, Illinois
University of Illinois at Chicago
Chicago, Illinois, United States, 60612
United States, New York
Mount Sinai School of Medicine
New York, New York, United States, 10029
Weill Cornell
New York, New York, United States, 10065
United States, Utah
University of Utah
Salt Lake City, Utah, United States, 84102
Italy
University of Florence
Florence, Italy
Sponsors and Collaborators
Icahn School of Medicine at Mount Sinai
Myeloproliferative Disorders-Research Consortium
National Cancer Institute (NCI)
Investigators
Study Chair: Josef Prachal, MD Myeloproliferative Disorders-Research Consortium
  More Information

Responsible Party: Icahn School of Medicine at Mount Sinai
ClinicalTrials.gov Identifier: NCT00666289     History of Changes
Other Study ID Numbers: GCO 07-0548-00105
P01CA108671-01A2 ( U.S. NIH Grant/Contract )
MPD-RC 105 ( Other Identifier: Myeloproliferative Disorders-Research Consortium )
First Submitted: April 22, 2008
First Posted: April 24, 2008
Last Update Posted: September 4, 2017
Last Verified: September 2017

Keywords provided by Icahn School of Medicine at Mount Sinai:
polycythemia vera
essential thrombocythemia
idiopathic myelofibrosis
family clusters

Additional relevant MeSH terms:
Primary Myelofibrosis
Polycythemia
Polycythemia Vera
Thrombocytosis
Thrombocythemia, Essential
Myeloproliferative Disorders
Bone Marrow Diseases
Hematologic Diseases
Bone Marrow Neoplasms
Hematologic Neoplasms
Neoplasms by Site
Neoplasms
Blood Platelet Disorders
Blood Coagulation Disorders
Hemorrhagic Disorders